At a glance
ClinicalIndex Comparison Record- ✓Age >18 years
- ✓First or second renal transplant alone or combined with pancreas transplantation
- ✓Adequate baseline biopsy with at least 10 cortical projection fields
- ✕Age <18 years
- ✕Serum creatinine ≥2.5 mg/dL
- ✕Persistent hyperkalemia (potassium >5.4 mEq/L)
- ✕Known hypersensitivity to losartan or iodine allergy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Angiotensin II Blockade for the Prevention of Cortical Interstitial Expansion and Graft Loss in Kidney Transplant Recipients
In Brief
A Phase 4 clinical trial evaluating Losartan 100mg and Placebo for Kidney Disease and Proteinuria. Completed, enrolled 153 participants across 2 sites.
Detailed Summary
Chronic allograft nephropathy continues to be a major cause of kidney transplant loss and return to dialysis. Treatment options are limited and the course of the disease tends to be progressive. This trial is designed to prevent a major mediator of this process, namely the expansion of the cortical interstitial compartment of the kidney where most of the scarring occurs. The drug being studied, Losartan, has proven efficacious in a number of kidney diseases.
Study Details
Timeline
Interventions
To be started within three months of transplant and continued for five years.
No treatment with continued follow-up for five years.